Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Brought to you by

Celgene pays $1.1bn up front to buy Impact; $5.9bn in earn-outs possible

Executive Summary

Celgene Corp. is paying $1.1bn up front, plus massive potential earn-outs, to acquire privately held cancer drug developer Impact Biomedicines.
Deal Industry
  • Biotechnology
  • Pharmaceuticals
Deal Status
  • Final
Deal Type
  • Acquisition
    • Full Acquisition
    • Payment Includes Cash
    • Includes Earnout
    • Intra-Biotech Deal
    • Acquisition of Private Biotech

Related Companies